Future of the Respiratory Disease Vaccine Market: Insights, Developments, and Strategic Overview

 Offering reliable and timely data, this report is a key resource for anyone building or refining their respiratory disease vaccine industry roadmap.

Respiratory Disease Vaccine Market Valuation Forecast: What Will The Market Be Worth By 2025?
The respiratory disease vaccine market size has grown marginally in recent years. It will grow from $69.99 billion in 2024 to $70.03 billion in 2025 at a compound annual growth rate (CAGR) of 0.1%. The growth in the historic period can be attributed to rising prevalence of respiratory diseases, increased public vaccination awareness, public health initiatives, growing demand for effective and more tolerable vaccines.

The respiratory disease vaccine market size is expected to see steady growth in the next few years. It will grow to $77.48 billion in 2029 at a compound annual growth rate (CAGR) of 2.6%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, investments in vaccine, pandemic preparedness. Major trends in the forecast period include innovative vaccines, collaborative research, advancement in vaccine development, drug approval.

Get your free sample today:
Respiratory Disease Vaccine Market 2025, Growth And Insights Sample

What Are The Key Factors Driving Growth In The Respiratory Disease Vaccine Market?
The increasing incidence of tuberculosis is expected to propel the growth of the respiratory disease vaccine market going forward. Tuberculosis (TB) is a type of respiratory disease caused by the bacterium Mycobacterium tuberculosis, which primarily affects the lungs and potentially impacts other organs and systems in the body, leading to various complications. The increasing incidence of tuberculosis can catalyze efforts to develop and distribute respiratory disease vaccines to reduce the spread of tuberculosis. For instance, in November 2023, according to the Centers for Disease Control and Prevention, a US-based Government agency, in 2022, the United States reported 8,331 tuberculosis (TB) cases, marking a 5.9% increase in case count compared to 2021. The incidence rate rose to 2.5 cases per 100,000 people, reflecting a 5.5% increase from the previous year. Therefore, the increasing incidence of tuberculosis will drive the respiratory disease vaccine market.

Emerging And High-Growth Segments In The Global Respiratory Disease Vaccine Market
The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections
3) By Age: Infant, Adolescent, Adult
4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:
1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine
2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine
3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Respiratory Disease Vaccine Market Future Trends
Major companies operating in the respiratory disease vaccine market are concentrating on creating innovative products to enhance their efficacy and provide improved solutions for preventing and treating respiratory disease infections. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical company, received Food and Drug Administration (FDA) approval for ABRYSVO (Respiratory Syncytial Virus Vaccine), the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older. ABRYSVO is an unadjuvanted vaccine made up of a pair of preF proteins tailored to maximize immunity to RSV A and B varieties and it has been clinically proven to be safe and productive.

Key Respiratory Disease Vaccine Company Insights:
Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

View the full respiratory disease vaccine market report here:
Respiratory Disease Vaccine Market 2025, Growth And Insights

How Does Respiratory Disease Vaccine Market Growth Vary Across Major Regions?
Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Contact Us:

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: The Business Research Company | LinkedIn